摘要
目的观察新型毒蕈咸受体拮抗药托特罗定治疗特发性膀胱过度活动症的有效性和安全性。方法将托特罗定1mg呼奥昔布宁5mg及安慰剂进行对比,疗程3周。夜间入睡前2h口服。结果与安慰剂相比,托特罗定和奥昔布宁都使入睡前1h夜尿次数(P<0.01)显著减少。两种药物的副作用主要为口干。在口干(发生率和强度)方面,托特罗定要明显优于奥昔布宁(P<0.05)。结论托特罗定治疗特发性膀胱过度活动症效果明确,疗程3周即能达到疗效。尽管奥昔布宁也具有很好的疗效,但不良反应限制了它的应用。
Objective To examine the safety,efficacy and t olerability of tolterodine in randomized,doubled-blind,3weeks study of patients with idiopathic overactiv e bladder(IOAB).Method Study compared tolterodine(lmg )to oxybutynin(5mg )and placebo taking 2hour before going to bed at night.Changes in micturition diary variables were evaluated after 3weeks' treatment.Result Both tolterodine and oxybutynin significantly decrease d the number of micturiton /lh from baseline,compared to placebo.The most common adverse effect was dry mouth.Tolterodine was tolerated significantly better than oxybutynin when dry mouth(both frequency and intensity)were consid-ered.Conclusion Although oxybutynin is highly effective,its clinical utility is limite d by side effect.Patients receiving tolterodine should not experience hese limitations and instead will get safe and long-term effe ctive treatment.
出处
《中国临床康复》
CSCD
2002年第20期3100-3101,共2页
Chinese Journal of Clinical Rehabilitation
